Saturday, April 4, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking with Mr. Zach Baron, Director of the Health Policy and the Law Initiative at the O’Neill Institute

Launched in February 2023, the Health Care Litigation Tracker is a free digital resource that tracks and analyzes health care litigation in the United States. The tracker contains current health policy litigation cases, with an emphasis on health care access, coverage, affordability, transparency, and equity.

Zachary Baron is a director of the Health Policy and the Law Initiative at the O’Neill Institute. He focuses on providing technical assistance for policymakers and public education on health policy legal issues with an emphasis on access to coverage, affordability, transparency, and equity.

Cases discussed in the conversation are:

American College of Pediatricians et al. v. Becerra et al.

https://litigationtracker.law.georgetown.edu/litigation/american-college-of-pediatricians-et-al-v-becerra-et-al-2/

Barrows et al v. Humana, Inc.

https://litigationtracker.law.georgetown.edu/litigation/barrows-et-al-v-humana-inc/

Eli Lilly and Company et al. v. U.S. Department of Health and Human Services et al.

https://litigationtracker.law.georgetown.edu/litigation/eli-lilly-and-company-et-al-v-u-s-department-of-health-and-human-services-et-al/

 

#health #law #oneillinstitute #georgetown #policy

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!